人附睾蛋白4(HE4)在恶性肿瘤中的表达与临床进展  

Expression of Human Epididymis Protein 4 in Cancer and its Clinical Progress

作　　者：唐雨曦[1] 罗晨辉[2,3] 王瑛 王静[2,3] 

机构地区：[1]南华大学,湖南衡阳421001 [2]湖南省肿瘤医院 [3]中南大学湘雅医学院附属肿瘤医院,湖南长沙410013

出　　处：《肿瘤药学》2015年第2期87-91,共5页Anti-Tumor Pharmacy

基　　金：湖南省科技厅重点项目资助(2013FJ2009)

摘　　要：人附睾蛋白4(human epididymis protein-4,HE4)是具有免疫保护作用的蛋白酶抑制剂家族的成员,可在血清及组织中检测到其表达,在正常组织中呈低表达,在肿瘤组织中呈高表达。目前,国内外已有多项研究表明HE4与卵巢癌、子宫内膜癌、肺癌、膀胱癌等肿瘤有关,且其敏感度与特异性均优于CA125,美国FDA已批准将其作为一个新的肿瘤标志物用于卵巢肿瘤的疗效及复发的监测。本文主要对HE4在各种恶性肿瘤中的表达与临床应用进展进行综述。Human epididymis protein 4（HE4） is one member of the protease inhibitor family which have the immune protective effect. It can be detected in serum and tissues, presenting low expression in normal tissues but over expression in tumor tissues. Nowadays, numerous studies showed that HE4 has relationship with ovarian cancer, endometrial cancer, lung cancer and bladder cancer, etc. Besides, since it has a higher sensitivity and specificity than CA125, HE4 has been approved by FDA as a new tumor marker for diagnosis of ovarian cancer in early stage. In this article, we reviewed the expression patterns of HE4 in various malignant neoplasms and its clinical application progress.

关 键 词：人附睾蛋白4 卵巢癌 子宫内膜癌 肿瘤标志物 

分 类 号：R730.3[医药卫生—肿瘤]